2026-04-14T09:54:01Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/2455-3484.000021 2017-05-12 PTZ.JAMTS:VOL3

How the histamine N-methyltransferase inhibitor metoprine alleviates methamphetamine reward Nobue Kitanaka Junichi Kitanaka F Scott Hall Satoshi Okumura# Tomoyuki Sakamoto# George R UhlMotohiko Takemura<p>Methamphetamine (METH) is a highly addictive psychomotor stimulant drug that is abused worldwide [1].<br>METH abuse results in numerous adverse effects after acute administration, as well as an array of adverse outcomes associated with binge use, long-term use, and withdrawal [2- 4]. Acutely METH releases dopamine from synaptic terminals through multiple actions that include inducing reverse transport of dopamine via the dopamine transporter (DAT), impairing the function of the vesicular monoamine transporter-2 (VMAT2), leading to increased cytoplasmic dopamine concentrations,<br>and inhibition of monoamine oxidase [5-8]. Moreover, these changes contribute to the production of oxidative metabolites, metabolic impairments, oxidative damage to dopamine terminals, and depletion of tissue dopamine levels [9-11]. METH and related drugs consequently produce broad effects on the central nervous system both acutely and chronically [12-14].<br></p> Journal of Addiction Medicine and Therapeutic Science - Peertechz Publications 2017-05-12 Review Article https://doi.org/10.17352/2455-3484.000021 en Copyright © Nobue Kitanaka et al.